BWAY
BrainsWay Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
69.56
PEG
0.43
P/B
7.08
P/S
9.62
EV/EBITDA
76.04
DCF Value
$-6.20
FCF Yield
3.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.4%
Operating Margin
8.3%
Net Margin
14.6%
ROE
12.0%
ROA
7.3%
ROIC
5.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $14.6M | $3.0M | $0.14 |
| FY 2025 | $52.6M | $7.7M | $0.36 |
| Q3 2025 | $13.5M | $1.6M | $0.04 |
| Q2 2025 | $12.6M | $2.0M | $0.05 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
1.20
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.